Abstract | BACKGROUND: METHODS: A systematic literature search was conducted using the meta-database of the German Institute of Medical Documentation and Information. Criteria of the Scottish Intercollegiate Guidelines Network were used to assess the quality of the controlled trials and systematic reviews/meta-analyses. RESULTS: Of the 806 retrieved records, 40 publications were included. For bevacizumab, efficacy in combination with fluoropyrimidine-based chemotherapy in first- and subsequent-line settings has been shown. The benefit of continued VEGF targeting has also been demonstrated with aflibercept and regorafenib. Cetuximab is effective with fluoropyrimidine, leucovorin, and irinotecan (FOLFIRI) in first-line settings and as a single agent in last-line settings. Efficacy for panitumumab has been shown with oxaliplatin with fluoropyrimidine in first-line settings, with FOLFIRI in second-line settings, and as monotherapy in last-line settings. Treatment of anti-EGFR antibodies is restricted to patients with tumors that do not harbor mutations in Kirsten rat sarcoma and in neuroblastoma RAS. CONCLUSION: Among various therapeutic options, the future challenge will be a better selection of the population that will benefit the most from specific anti- VEGF or anti- EGFR treatment and a careful consideration of therapy sequence.
|
Authors | Martha M Kirstein, Ansgar Lange, Anne Prenzler, Michael P Manns, Stefan Kubicka, Arndt Vogel |
Journal | The oncologist
(Oncologist)
Vol. 19
Issue 11
Pg. 1156-68
(Nov 2014)
ISSN: 1549-490X [Electronic] England |
PMID | 25326159
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Copyright | ©AlphaMed Press. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Organoplatinum Compounds
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Oxaliplatin
- Bevacizumab
- Panitumumab
- Irinotecan
- EGFR protein, human
- ErbB Receptors
- Leucovorin
- Fluorouracil
- Camptothecin
|
Topics |
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Bevacizumab
- Camptothecin
(administration & dosage, analogs & derivatives)
- Colorectal Neoplasms
(drug therapy, metabolism)
- ErbB Receptors
(metabolism)
- Fluorouracil
(administration & dosage)
- Humans
- Irinotecan
- Leucovorin
(administration & dosage)
- Molecular Targeted Therapy
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
- Panitumumab
- Vascular Endothelial Growth Factor A
(metabolism)
|